Prolonged-Release Fampridine Treatment and Walking Ability and Balance in Patients with Multiple Sclerosis: Results of the Randomized, Double-Blind MOBILE Study

被引：0
作者：
Lycke, Jan
Short, Christine
Gasperini, Claudio
Hupperts, Raymond
McNeil, Manjit
Medori, Rossella
Mehta, Lahar
Elkins, Jacob
机构：
来源：
NEUROLOGY | 2014年 / 83卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E36 / E36
页数：1
相关论文
共 50 条
  • [41] Prolonged-release fampridine shows consistent efficacy across sub-groups of multiple sclerosis patients
    Stourac, P.
    Putzki, N.
    [J]. JOURNAL OF NEUROLOGY, 2012, 259 : S152 - S153
  • [42] IMPACT OF PROLONGED-RELEASE FAMPRIDINE ON FATIGUE AMONG PEOPLE WITH MULTIPLE SCLEROSIS IN A MULTI-COUNTRY STUDY
    Kobelt, G.
    Acosta, C.
    Zhou, J.
    Harrington, A.
    Kinter, E.
    Dong, S.
    Hou, Q.
    [J]. VALUE IN HEALTH, 2018, 21 : S352 - S352
  • [43] Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
    Goodman, Andrew D.
    Brown, Theodore R.
    Krupp, Lauren B.
    Schapiro, Randall T.
    Schwid, Steven R.
    Cohen, Ron
    Marinucci, Lawrence N.
    Blight, Andrew R.
    [J]. LANCET, 2009, 373 (9665) : 732 - 738
  • [44] Multiple sclerosis patients concurrently treated with disease-modifying therapies show clinically meaningful increases in walking speed with prolonged-release fampridine
    Kieseier, B.
    Schapiro, R.
    Goodman, A.
    Putzki, N.
    [J]. JOURNAL OF NEUROLOGY, 2011, 258 : 261 - 261
  • [45] Long-term effects of fampridine on walking ability in patients with multiple sclerosis: a double-blind, placebo-controlled, monocenteric phase II study (FAMPKIN-EXT)
    Meyer, C.
    Filli, L.
    Kapitza, S.
    Loerincz, L.
    Weller, D.
    Farkas, M.
    Reuter, K.
    Zoerner, B.
    Linnebank, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 608 - 609
  • [46] Walking in multiple sclerosis improves with tDCS: a randomized, double-blind, sham-controlled study
    Pilloni, Giuseppina
    Choi, Claire
    Shaw, Michael T.
    Coghe, Giancarlo
    Krupp, Lauren
    Moffat, Marilyn
    Cocco, Eleonora
    Pau, Massimiliano
    Charvet, Leigh
    [J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2020, 7 (11): : 2310 - 2319
  • [47] Long-term safety and efficacy of prolonged-release fampridine in Japanese patients with multiple sclerosis (MS): Results from the motion Japan Part b study
    Saida, T.
    Yokoyama, K.
    Masaki, K.
    Ling, Y.
    McNeill, M.
    Lima, G.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 779 - 780
  • [48] Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study
    Goodman, A. D.
    Cohen, J. A.
    Cross, A.
    Vollmer, T.
    Rizzo, M.
    Cohen, R.
    Marinucci, L.
    Blight, A. R.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 (03): : 357 - 368
  • [49] The use of brain stimulation in the rehabilitation of walking disability in patients with multiple sclerosis: A randomized double-blind clinical trial study
    Oveisgharan, Shahram
    Karimi, Zahra
    Abdi, Siamak
    Sikaroodi, Hajir
    [J]. IRANIAN JOURNAL OF NEUROLOGY, 2019, 18 (02) : 57 - 63
  • [50] Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial
    Kanhai, Kawita M. S.
    Bijvank, Jenny A. Nij
    Wagenaar, Yorick L.
    Klaassen, Erica S.
    Lim, KyoungSoo
    Bergheanu, Sandrin C.
    Petzold, Axel
    Verma, Ajay
    Hesterman, Jacob
    Wattjes, Mike P.
    Uitdehaag, Bernard M. J.
    van Rijn, Laurentius J.
    Groeneveld, Geert Jan
    [J]. CNS NEUROSCIENCE & THERAPEUTICS, 2019, 25 (06) : 697 - 703
12345